Form 483

Pyramid Laboratories, Inc. Form 483, 2026-02-13

FDA issued a Form 483 to Pyramid Laboratories, Inc. on 2026-02-13 with 2 public-safe observations.

483· Form 483 issuedHuman Drugs2 observations

Pyramid Laboratories, Inc. · Costa Mesa, United States · Issued February 13, 2026

Overview

  • 2 public-safe observations are available for this inspection.
  • 2 structured CFR citations are represented.
  • 7 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

13 Feb 2026
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Bryan A Galvez, Sangeeta M Khurana, Joan M Cantellops Figueroa, Cecilia H Kieu, Navneet Kaur, Ana-Maria A Plapcianu, Aranjeet Singh

13 Feb 2026
21 CFR 211.65(a)

Equipment construction - reactive surfaces

Cited by Bryan A Galvez, Sangeeta M Khurana, Joan M Cantellops Figueroa, Cecilia H Kieu, Navneet Kaur, Ana-Maria A Plapcianu, Aranjeet Singh

Inspected site

PLPyramid Laboratories, Inc.Costa Mesa, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.65(a)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 2 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere